Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Stock Forecast

Stock Price Forecast

The 4 analysts that cover Supernus Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $63.25, which forecasts a 39.84% increase in the stock price over the next year. The lowest target is $60 and the highest is $65.

Price Target: $63.25 (+39.84%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$60	$63.25	$65	$65
Change	+32.66%	+39.84%	+43.71%	+43.71%

* Price targets were last updated on Oct 29, 2025.

Analyst Ratings

The average analyst rating for Supernus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25
Strong Buy	0	0	0	2	2	2
Buy	0	1	1	2	2	2
Hold	2	1	1	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Pavan Patel B of A Securities	B of A Securities	Strong Buy Initiates $65	Strong Buy	Initiates	$65	+43.71%	Oct 29, 2025
Stacy Ku TD Cowen	TD Cowen	Strong Buy Maintains $45 → $60	Strong Buy	Maintains	$45 → $60	+32.66%	Oct 23, 2025
David Amsellem Piper Sandler	Piper Sandler	Hold → Buy Upgrades $40 → $65	Hold → Buy	Upgrades	$40 → $65	+43.71%	Oct 9, 2025
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $46 → $63	Buy	Maintains	$46 → $63	+39.29%	Sep 30, 2025
David Amsellem Piper Sandler	Piper Sandler	Hold Maintains $36 → $40	Hold	Maintains	$36 → $40	-11.56%	Aug 29, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

716.89M

Increased by 8.32%

from 661.82M

Revenue Next Year

884.36M

Increased by 23.36%

from 716.89M

EPS This Year

2.83

Increased by 114.56%

from 1.32

EPS Next Year

3.73

Increased by 31.81%

from 2.83

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	520.40M	579.78M	667.24M	607.52M	661.82M	716.89M	884.36M
Revenue Growth	32.50%	11.41%	15.09%	-8.95%	8.94%	8.32%	23.36%
EPS	2.36	0.98	1.04	0.02	1.32	2.83	3.73
EPS Growth	12.38%	-58.48%	6.32%	-98.08%	6,500.00%	114.56%	31.81%
Forward PE	-	-	-	-	-	15.97	12.12
No. Analysts	-	-	-	-	-	8	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	745.5M	947.6M
Avg	716.9M	884.4M
Low	678.4M	807.6M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	12.6%	32.2%
Avg	8.3%	23.4%
Low	2.5%	12.7%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	2.99	4.49
Avg	2.83	3.73
Low	2.58	3.19

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	126.7%	58.7%
Avg	114.6%	31.8%
Low	95.3%	12.5%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.